Home › Insulin Resistance › NCT04482374

Puberty Suppression and Cardiometabolic Health

Effects of Puberty and Pubertal Suppression on Insulin Sensitivity, Metabolic Rate and Vascular Health

Who can join

Ages 9 to 14 · Men

Inclusion Criteria:

* Identify as a transgender female or cisgender male
* Age 9-14 years at the time of enrollment
* Tanner Stage 2-3 baseline pubertal development
* Plan to start gonadotropin releasing hormone analogue clinically in \< 2 months (for transgender females only)

Exclusion Criteria:

* Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures
* Type 1 or 2 diabetes (by medical history)
* On any medications that affect insulin sensitivity (e.g. metformin, antipsychotics)
* Hypertension (resting BP ≥ 140/90 mm/Hg)
* Weight \> 400 lbs
* On estrogen- or progesterone-containing medications at baseline
* \>3 hours of moderate-to-vigorous physical activity on the 3DPAR at the screening visit

About the study

This observational study will evaluate the effect of puberty suppression on insulin sensitivity, metabolic rate and vascular health among transgender female youth at baseline and 6 months after initiation of a gondoatropin releasing hormone agonist compared to matched cisgender male controls.

Sponsor: University of Colorado, Denver · Participants: 30 · Started: Aug 10, 2020

Contact the study team

• Natalie J Nokoff, MD, MSCS · Phone: 720-777-6128

Official record on ClinicalTrials.gov — NCT04482374

Locations in the U.S.

Conditions

• Insulin Resistance

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.